Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.41 |
| ▸ | KRAS | P01116 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL252459 | 0.84 | IDO1 (0.38) | ADORA1IDO1LMNAKDM4ENPC1 | |
| SCHEMBL246126 | 0.84 | IDO1 (0.38) | ADORA1IDO1LMNAKDM4ENPC1 | |
| SCHEMBL252434 | 0.79 | LMNA (0.36) | GCKLMNANPC1GAAMAPT | |
| SCHEMBL252433 | 0.79 | LMNA (0.36) | GCKLMNANPC1GAAMAPT | |
| SCHEMBL248608 | 0.79 | KDM4E (0.40) | ADORA1KRASADORA2ALMNAKDM4E | |
| SCHEMBL16585129 | 0.77 | PIK3CD (0.53) | LMNA | |
| SCHEMBL20067852 | 0.77 | PIK3CD (0.49) | LMNAKDM4ENPC1GAAMAPT | |
| SCHEMBL4182569 | 0.77 | PIK3CD (0.53) | LMNA | |
| SCHEMBL15302917 | 0.77 | PIK3CD (0.49) | LMNAKDM4ENPC1GAAMAPT | |
| SCHEMBL20072410 | 0.76 | PIK3CD (0.41) | IDO1KDM4ENPC1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759371-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759371-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759371-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2588468-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2588468-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2588468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130085151-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085151-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085151-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2012003262-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003262-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085151-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | ADORA1 3485/4885KRAS 659/4885ADORA2A 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.